Industry funding and placebo quit rate in clinical trials of nicotine replacement therapy: A commentary on etter et al. (2007)

Addiction

Volumn 105, Issue 12, 2010, Pages 2217-2218

  Greene, Natasha M P ^a   Taylor, Eleanor M ^a   Gage, Suzanne H ^a   Munafó, Marcus R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Clinical trials; Industry funding; Nicotine replacement therapy; Placebo effect; Smoking cessation; Tobacco use

Indexed keywords

NICOTINE; NICOTINIC AGENT; PLACEBO;

CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; HUMAN; NOTE; SMOKING CESSATION; STATISTICS;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HUMANS; NICOTINE; NICOTINIC AGONISTS; PLACEBOS; SMOKING CESSATION;

EID: 78249232641     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03155.x     Document Type: Letter

References (5)

1. Etter J. F., Burri M., Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis. Addiction 2007; 102: 815-22.
2. Fava M., Evins A. E., Dorer D. J., Schoenfeld D. A. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115-27.
3. Stead L. F., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; CD000146.
4. Stein D. J., Baldwin D. S., Dolberg O. T., Despiegel N., Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006; 67: 1741-6.
5. Walsh B. T., Seidman S. N., Sysko R., Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-7.